Publicaties

2017 Journal of the COPD Foundation The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials

2017 BioMed Central (Respiratory Research) Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence

2017 KAMADA
Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference

2017 Medisch Contact Trek vergoeding behandeling erfelijk longemfyseem gelijk

2016 European Respiratory Journal (ERJ) Efficacy of augmentation therapy for emphysema associated with α1-antitrypsin deficiency: enough is enough

2016 Alpha-1 Foundation (US) RAPID trial extension study finds augmentation therapy slows disease progression, supports early intervention

2016 The Lancet, (RAPID-OLE) an open-label extension trial: Long-term efficacy and safety of Alpha-1 proteinase inhibitor treatment for emphysema caused by severe Alpha-1 antitrypsin deficiency

2016 DeMorgen. Kom ook op tegen de vaakst voorkomende zeldzame ziekte (België)

2016 Nederlands Tijdschrift voor Geneeskunde (NTvG) Twee zussen met Longemfyseem

2015 European Medicines Agency (EMA) Europees Openbaar Beoordelingsrapport (EPAR) voor Respreeza (CSL Behring)

2015 European Medicines Agency (EMA) Approval Respreeza (CSL Behring)

2014 Alpha-1 Foundation (Amerika)

2012 Westfälische Nachrichten (Münster, Duitsland)

2008 Nederlands Tijdschrift voor Dermatologie en Venereologie